NEW YORK, March 6, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN).Shareholders who purchased shares of REGN during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/regeneron-pharmaceuticals-inc-loss-submission-form/?id=134032&from=4 CLAS ...

Core Insights - The report titled "Inclusion Body Myositis - Pipeline Insight, 2025" provides a comprehensive overview of the current pipeline for Inclusion Body Myositis (IBM), highlighting the efforts of over 2 companies and the development of more than 3 pipeline drugs projected until 2025 [2][4]. Group 1: Understanding Inclusion Body Myositis - Inclusion Body Myositis is a progressive muscle disorder primarily affecting adults over 50, with an estimated patient population exceeding 50,000 in the U.S. and Europe [3]. - The report addresses both symptomatic and pathophysiological aspects of IBM, along with insights into diagnostic methodologies and current treatment paradigms [3]. Group 2: Current Treatment Landscape - There are currently no approved therapeutic options specifically for IBM, and existing treatments like immunosuppressants and corticosteroids have shown limited efficacy [4]. - The report discusses various strategies under investigation to meet the unmet medical needs in this therapeutic area [4]. Group 3: Advancements in the Therapeutic Pipeline - The report highlights emerging drugs in the IBM pipeline, including ABC008 by Abcuro, Inc., which is an anti-KLRG1 antibody currently in Phase II/III trials targeting cytotoxic T cells involved in IBM [5]. Group 4: Strategic Developments and Future Outlook - The report details pipeline development activities such as collaborations, acquisitions, mergers, and licensing that are shaping the future of IBM treatments [6]. - These strategic developments may provide new pathways for improving care and management for individuals affected by IBM [6].

PHILADELPHIA, March 5, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) on behalf of purchasers of Regeneron securities between November 2, 2023 through October 30, 2024, inclusive (the "Class Period").Investor Deadline: Investors who purchased or acquired REGENERON securities during the Class Period may, no later than MARCH 10, 2025, seek to be appointed as a ...

Group 1 - Regeneron Pharmaceuticals participated in the TD Cowen 45th Annual Health Care Conference, highlighting its ongoing engagement with investors and analysts [1] - Marion McCourt, Chief Commercial Officer, and Ryan Crowe, Senior Vice President of Investor Relations, represented the company during the conference [1] - The conference included a forward-looking statement disclaimer, indicating that remarks may involve risks and uncertainties that could affect actual results [3] Group 2 - The discussion began with a focus on the EYLEA franchise, with inquiries about its latest developments and key catalysts for growth in 2025 [4]

Core Viewpoint - A class action securities lawsuit has been filed against Regeneron Pharmaceuticals, alleging securities fraud that affected investors between November 2, 2023, and October 30, 2024 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Regeneron made false statements and concealed payments made to distributors to cover credit card fees, which misled investors about the pricing and sales of Eylea [2]. - It is alleged that these payments allowed Regeneron to offer price concessions that lowered Eylea's selling price, misleadingly boosting reported sales figures [2]. - The complaint also states that Regeneron failed to report these payments as price concessions, resulting in an overstatement of the Average Selling Price (ASP) reported to federal agencies, thus violating the False Claims Act [2]. Group 2: Investor Actions - Investors who suffered losses during the specified timeframe have until March 10, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating a no-cost participation model [3]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4].

Regeneron Pharmaceuticals, Inc. (REGN) obtained positive opinion for its pipeline candidate linvoseltamab from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).The CHMP recommended conditional marketing authorization of linvoseltamab to treat adults with relapsed and refractory (R/R) multiple myeloma (MM). The recommendation is specific to those who have received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory agent and an anti ...

Core Viewpoint - The Rosen Law Firm is reminding investors who purchased Regeneron Pharmaceuticals, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Regeneron securities between November 2, 2023, and October 30, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 10, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Allegations Against Regeneron - The lawsuit alleges that Regeneron made false and misleading statements regarding its pricing practices for Eylea, including undisclosed payments to distributors that affected the selling price [5]. - Specific claims include that Regeneron’s actions misled investors about the true sales figures and violated the False Claims Act by overstating the Average Sales Price reported to federal agencies [5]. - The lawsuit asserts that when the true details were revealed, investors suffered damages due to the misleading nature of Regeneron's statements about its business and operations [5]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm emphasizes its experience and success in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - The firm has been consistently ranked among the top firms for securities class action settlements since 2013 [4].

TARRYTOWN, N.Y., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending conditional marketing authorization of linvoseltamab to treat adults with relapsed and refractory (R/R) multiple myeloma (MM). The recommendation is specific to those who have received at least three prior therapies, including a proteasome inhibitor, an imm ...

NEW YORK, Feb. 28, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Regeneron investors who were adversely affected by alleged securities fraud between November 2, 2023 and October 30, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/regeneron-ph ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Regeneron To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $100,000 in Regeneron between November 2, 2023 and October 30, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Feb. 27, 2025 /PRN ...